MedTrace Logo

The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End Products

NCT02768220 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2018-02-15

No results posted yet for this study

Summary

Single-center open-label multiple dose randomized two period cross-over study to examine Advanced Glycation End Product (AGE) levels in human subjects pre and post empagliflozin administration.

Conditions

  • SGLT-2 Inhibitors
  • Advanced Glycation End Products
  • Diabetes

Interventions

DRUG

empagliflozin

Test to see how 30 days of jardiance changes serum and urinary advanced glycation end product levels

DRUG

linagliptin

Test to see how 30 days of tradjenta changes serum and urinary advanced glycation end product levels

Sponsors & Collaborators

  • Northwell Health

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-12-01
Primary Completion
2018-08-31
Completion
2018-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02768220 on ClinicalTrials.gov